[vc_row type=”full_width_background” full_screen_row_position=”middle” bg_image=”1643″ bg_position=”center center” bg_repeat=”no-repeat” scene_position=”center” text_color=”light” text_align=”center” top_padding=”300″ bottom_padding=”300″ color_overlay=”#243746″ overlay_strength=”0.5″ shape_divider_position=”bottom” bg_image_animation=”none” shape_type=””][vc_column column_padding=”no-extra-padding” column_padding_position=”all” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”none” width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” column_border_style=”solid” bg_image_animation=”none”][vc_column_text]
TVB-2640
[/vc_column_text][/vc_column][/vc_row][vc_row type=”full_width_background” full_screen_row_position=”middle” bg_color=”#f5f5f5″ scene_position=”center” text_color=”dark” text_align=”center” top_padding=”5%” bottom_padding=”5%” class=”passport” overlay_strength=”0.3″ shape_divider_position=”bottom” bg_image_animation=”none” shape_type=””][vc_column column_padding=”padding-5-percent” column_padding_position=”all” background_color=”#ffffff” background_color_opacity=”1″ background_hover_color_opacity=”1″ column_link_target=”_self” column_shadow=”none” column_border_radius=”5px” top_margin=”-250″ width=”1/1″ tablet_width_inherit=”default” tablet_text_alignment=”default” phone_text_alignment=”default” column_border_width=”none” bg_image_animation=”none”][vc_column_text max_width=”800″]
We have created a platform of proprietary, selective FASN inhibitors.
[divider line_type=”No Line” custom_height=”20″]Our lead product candidate TVB-2640 is an oral, highly potent, selective and reversible, first-in-class inhibitor of FASN. TVB-2640 is rapidly absorbed in human with well-behaved pharmacokinetics.
Our early clinical development strategy provided proof of concept for target engagement and inhibition of de novo lipogenesis by TVB-2640 in relevant patient populations.[/vc_column_text][/vc_column][/vc_row]
